Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2023 Jan 25:2023:9195157.
doi: 10.1155/2023/9195157. eCollection 2023.

Clinical Significance of Different Profiles of anti-Ro Antibodies in Connective Tissue Diseases

Hai-Tao Yang  1 , Xiao-Ping Hong  1 , Jie-Wen Guo  2 , Xiao-Ling Zhong  3 , Rui Liao  2 , Cui-Lian Liu  1 , Li-Xiong Liu  1 , Kai Li  1 , Yu-Lan Chen  1 , Dong-Zhou Liu  1
Affiliations

Clinical Significance of Different Profiles of anti-Ro Antibodies in Connective Tissue Diseases

Hai-Tao Yang et al. J Immunol Res. .

Abstract

Objective: Anti-Ro60 and anti-Ro52 antibodies are associated with different connective tissue diseases (CTDs). However, the clinical significance of anti-Ro antibodies is not always consistent among different global regions. The aim of this study was to investigate the clinical characteristics of patients with anti-Ro antibodies.

Methods: A total of 1596 inpatients with anti-Ro antibodies were included in the study. Demographic, clinical, and serological data were compared between individuals with different profiles of anti-Ro antibodies: patients with anti-Ro52 antibodies alone, patients with anti-Ro60 antibodies alone, and patients with combined anti-Ro52 and anti-Ro60 antibodies.

Results: Of the 1596 patients, 1362 (85.3%) were female, the mean age was 45.5 years, and systemic lupus erythematosus (SLE) (46.0%) and Sjogren's syndrome (SS) (19.0%) were the most common CTD diagnoses. Among the patients with anti-Ro52 antibodies alone, idiopathic inflammatory myopathy (18.8%) and SLE (17.6%) were the most common CTD diagnoses. The coexistent autoantibodies of this group were significantly lower compared with those of the other two groups, while the presence of anti-Jo1 antibodies were significantly higher compared with those of the other two groups (3.7% vs. 0.6% vs. 1.9%, p = 0.029). In addition, the patients with isolated anti-Ro52 antibodies were more likely to suffer from interstitial lung disease (35.5% vs. 11.3% vs. 13.7%, p < 10-4) and pulmonary arterial hypertension (10.1% vs. 5.3% vs. 3.6%, p = 0.001) compared with the other two groups of patients. Compared with patients with isolated anti-Ro52 or anti-Ro60 antibodies, the patients with combined anti-Ro52 and anti-Ro60 antibodies were more likely to suffer from xerophthalmia and xerostomia. Furthermore, hypocomplementemia, hyperglobulinemia, and proteinuria were particularly prevalent in patients with anti-Ro60 antibodies.

Conclusion: Different profiles of anti-Ro antibodies were significantly associated with clinical phenotypic features in CTDs, indicating the potential diagnostic and prognostic value of these antibodies in clinical practice.

PubMed Disclaimer

Conflict of interest statement

The authors have declared that they have no competing interests.

Figures

Figure 1
Figure 1
Flow chart of patient inclusion and grouping.
Figure 2
Figure 2
Comparison of autoantibody profiles in patients with positive anti-Ro antibodies.
See this image and copyright information in PMC

References

    1. Scofield R. H. Autoantibodies as predictors of disease. Lancet . 2004;363(9420):1544–1546. doi: 10.1016/S0140-6736(04)16154-0. - DOI - PubMed
    1. Chan E. K., Hamel J. C., Buyon J. P., Tan E. M. Molecular definition and sequence motifs of the 52-kd component of human ss-a/ro autoantigen. The Journal of Clinical Investigation . 1991;87(1):68–76. doi: 10.1172/JCI115003. - DOI - PMC - PubMed
    1. Wolin S. L., Steitz J. A. The ro small cytoplasmic ribonucleoproteins: identification of the antigenic protein and its binding site on the ro rnas. Proceedings of the National Academy of Sciences of the United States of America . 1984;81(7):1996–2000. doi: 10.1073/pnas.81.7.1996. - DOI - PMC - PubMed
    1. Lee A. Y. S., Reed J. H., Gordon T. P. Anti-ro60 and anti-ro52/trim21: two distinct autoantibodies in systemic autoimmune diseases. Journal of Autoimmunity . 2021;124, article 102724 doi: 10.1016/j.jaut.2021.102724. - DOI - PubMed
    1. Boccitto M., Wolin S. L. Ro60 and y rnas: structure, functions, and roles in autoimmunity. Critical Reviews in Biochemistry and Molecular Biology . 2019;54(2):133–152. doi: 10.1080/10409238.2019.1608902. - DOI - PMC - PubMed

LinkOut - more resources